Status:
RECRUITING
Superiority Trial Evaluating Digitalized Information Media for Patients with Advanced Sarcomas Receiving Second Line Treatment.
Lead Sponsor:
Centre Oscar Lambret
Collaborating Sponsors:
Canceropôle Nord Ouest
Conditions:
Sarcoma Metastatic
Locally Advanced Soft Tissue Sarcoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving second-line t...
Detailed Description
ePPS-2202 is a phase 3, randomised,open-label, controlled, multicentre interventional study, designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard inf...
Eligibility Criteria
Inclusion
- Sarcomas of soft tissues or viscera ;
- Inoperable metastatic or locally advanced disease ;
- Indication for 2nd-line treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine after failure of 1st-line anthracycline therapy ;
- Patient covered by French social security ;
- Written, signed, informed consent ;
Exclusion
- Poor understanding of French ;
- Difficulty accessing a computer ;
- Pregnant or nursing woman ;
- Person deprived of liberty or under guardianship ;
- Impossibility of undergoing medical follow-up for geographical, social or psychological reasons.
Key Trial Info
Start Date :
May 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
377 Patients enrolled
Trial Details
Trial ID
NCT06211257
Start Date
May 29 2024
End Date
March 1 2028
Last Update
November 20 2024
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Léon Bérard
Lyon, Auvergne-Rhône-Alpes, France, 69373
2
CHU Jean Minjoz
Besançon, Bourgogne-Franche-Comté, France, 25000
3
Centre Eugène Marquis
Rennes, Brittany Region, France, 35042
4
Institut de Cancérologie Strasbourg
Strasbourg, Grand Est, France, 67033